NEW YORK--(BUSINESS WIRE)--April 21, 2006--Xenomics, Inc. (OTCBB:XNOM - News; FWB:XE7), a developer of next-generation medical DNA technologies, today announced that its senior scientists were invited to author an article about the medical potential of the Company’s proprietary DNA-based diagnostic testing platform for the “Expert Series” of respected scholarly medical and healthcare journal, Future Drugs.
The article, “Transrenal DNA Testing: Progress and Perspectives,” provides a detailed overview of the science and real-world potential medical applications of the Company’s patented molecular diagnostic technology, called Transrenal DNA (Tr-DNA). The article was written by Dr. Samuil R. Umansky, Xenomics President and co-founder, and Dr. L. David Tomei, PhD., who is the CEO as well as a co-founder.
“We have been asked to write this article because the medical and scientific communities are rapidly coming to understand the impact that our research on Transrenal DNA will have in the field,” said Dr. Tomei. “There is an awareness developing in the scientific community of our technology, its advantages, and its wide range of applications.”
Xenomics scientists were the first to discover that DNA from cells located inside the body can cross the kidney barrier and accumulate in the urine, and that through the analysis of easily obtained urine samples from patients, these highly novel Transrenal DNA fragments can provide vital information about a wide range of conditions inside the body, including serious infectious diseases, fetal development during pregnancy, cancer, and numerous other applications.
“A particularity important feature of our Tr-DNA diagnostic technology is that it is a true platform technology,” commented Dr. Tomei. “Unlike current clinical diagnostic tests that require a variety of often incompatible methods, techniques, and specimens, our Tr-DNA test is based upon the isolation and detection of DNA fragments with specific sequences or epigenic modifications.
“Other significant advantages of our Tr-DNA test is that the collection of urine samples is a non-invasive process and urine is stable and easy to handle unlike a blood specimen, which is classified as an infectious fluid,” continued Dr. Tomei. “The kidney filters DNA fragments from the circulatory system and presents a concentration of such material in the urine, which also enables our tests to be extremely sensitive and accurate. We believe Tr-DNA technology will foster fundamental improvements in safety, accuracy and functionality of diagnostic testing, currently a $1.5 billion segment of the healthcare industry.”
Xenomics intends to develop this platform into a pipeline of potentially groundbreaking commercial medical testing products for the detection and/or monitoring of diverse diseases and health conditions, including prenatal conditions, tuberculosis, HIV/AIDS, cancer, malaria and numerous others.
Interested investors and scientists can obtain a copy of this article from Future Drugs’ Expert Series by sending a request to Dr. Tomei at ldtomei@xenomics.com.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics’ patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a corresponding allowed European patent for the Company’s prenatal testing applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Istituto Nazionale per la Malattie Infettive “Lazarus Spallanzani”) in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more investor-specific information, including daily and historical Company stock quote data, recent news releases and an Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/xenomics. Xenomics is also listed on the Frankfurt Stock Exchange under the symbol XE7.
About Future Drugs:
Future Drugs provides healthcare practitioners and research professionals with a unique source of objective cutting-edge information on exciting emerging trends in healthcare and advances in the major therapeutic areas through the Expert Review series. The “Expert Review” series provides analysis and commentary on emerging opportunities, new strategies and the performance of new therapeutic and diagnostic modalities. All articles are subject to rigorous peer review by top international scientists and clinicians, and the finished articles make an essential contribution to decision-making. For more information, please visit: www.future-drugs.com
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as “expect,” “might,” “should,” “anticipate” and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in Xenomics’ Form SB-2 as filed with the Securities and Exchange Commission on March 15, 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics’ technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
Contact: Xenomics, Inc. L. David Tomei, 212-297-0808 or Financial Communications Trilogy Capital Partners, Inc. Paul Karon, 800-592-6067 paul@trilogy-capital.com
Source: Xenomics, Inc.
